NovoCure (NVCR) EBT (2014 - 2026)

NovoCure has disclosed EBT across 13 years of filings, most recently posting -$69.3 million for Q1 2026.

• EBT for Q1 2026 came in at -$69.3 million, down 128.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$175.2 million (down 34.97% YoY), and the FY2025 annual result was -$136.2 million, down 3.88% from the prior year.
• EBT came in at -$69.3 million for Q1 2026 at NovoCure, down from -$41.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$2.5 million in Q1 2022 to a low of -$69.3 million in Q1 2026.
• The 5-year median for EBT is -$32.6 million (2022), against an average of -$35.9 million.
• Across the five-year window, EBT plunged 1931.01% in 2023 and surged 57.83% in 2024, its largest moves.
• NovoCure's EBT stood at -$32.6 million in 2022, then retreated by 18.35% to -$38.5 million in 2023, then plunged by 43.27% to -$55.2 million in 2024, then rose by 25.82% to -$41.0 million in 2025, then sank by 69.11% to -$69.3 million in 2026.
• The last three EBT figures came in at -$69.3 million (Q1 2026), -$41.0 million (Q4 2025), and -$30.0 million (Q3 2025), per Business Quant data.